Medtronic Receives First-of-its-Kind FDA Approval for OmniaSecure™ Defibrillation Lead
Medtronic has received expanded U.S. Food and Drug Administration (FDA) approval for its OmniaSecure™ defibrillation lead, allowing its use for conduction system pacing (CSP) in the left bundle branch (LBB) area. This marks the first approval of a defibrillation lead for this type of physiologic pacing approach.
The OmniaSecure lead is designed to connect with implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds), which are used to treat serious heart rhythm disorders such as ventricular tachycardia and ventricular fibrillation.
The device is intended to deliver life-saving defibrillation therapy while also supporting more natural electrical activation of the heart.
The lead is the smallest defibrillation lead currently available and can be used in both adult and adolescent patients aged 12 and above.
It is based on Medtronic’s existing SelectSecure pacing technology and features a thin, lumenless design that allows precise catheter-based placement.
Clinical data from the LEADR LBBAP study supported the approval, showing high implantation success and low complication rates in conduction system pacing use. The study also indicated reliable defibrillation performance.
The system may also be used in left bundle branch optimized cardiac resynchronization therapy (LOT-CRT), which combines conduction system pacing with left ventricular pacing to improve synchronised heart function in selected patients.
The device was launched commercially in the United States in early 2026 following earlier FDA clearance for standard right ventricular use.
